OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5594
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 548
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 95
  • Lymphoma 235
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 517
  • Ovarian 65
  • Pancreatic 102
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40

Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE82...

Bradley Monk, MD, FACOG, FACS, Gynecologic Oncologist, Arizona Oncology speaks about the ESMO 2021 Abstract #LBA2, Presidential Symposium: KEYNOTE-826: A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy for First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

Link to Abstract:
https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019/keynote-826-a-phase-iii-randomized-study-of-chemotherapy-with-or-without-pembrolizumab-for-first-line-treatment-of-persistent-recurrent-or-metas


265TiP Abstract:

Background:

Patients with advanced cervical cancer have a significant chance of death and a poor prognosis. Although adding the anti-VEGF agent bevacizumab to platinum- and taxane-based chemotherapy (CT) is associated with a modest OS benefit compared to CT alone (median OS, 16.8 vs 13.3 mo; hazard ratio, 0.77, 95 percent CI, 0.62-0.95; P = 0.007; Tewari et al. Lancet. 2017), VEGF has emerged as a therapeutic target for these patients. The PD-1 inhibitor pembrolizumab was granted accelerated approval by the US FDA for patients with PD-L1–positive (combined positive score [CPS] of > 1) cervical cancer who had progressed during or after treatment based on an ORR of 14.3 percent (95 percent CI, 7.4-24.1) in the cervical cancer cohort of KEYNOTE-158 (Chung et al. J Clin Oncol. 2019). KEYNOTE-826 (NCT03635567) is a phase 3 randomized, double-blind, international trial evaluating the effectiveness and acceptability of CT in the first-line context with or without pembrolizumab and/or bevacizumab.

Design of the experiment:

Every three weeks, eligible patients with recurrent, persistent, or metastatic cervical cancer who have not previously had CT in a recurrent or metastatic context and are not susceptible to curative therapy will be randomized 1:1 to CT + pembrolizumab 200 mg or placebo. Before randomization, the investigator will choose the CT regimen (paclitaxel 175 mg/m2 + cisplatin 50 mg/m2 or carboplatin AUC 5, with or without bevacizumab 15 mg/kg). Metastasis status at diagnosis, planned bevacizumab usage (yes/no), and tumor PD-L1 CPS (1, 1 to 10, or 10) will all be used to stratify patients. Treatment will last 35 cycles (two years) or until illness progression, intolerable toxicity, or patient withdrawal. PFS per RECIST v1.1 (evaluated by blinded independent central review) and OS are the primary objectives. ORR, the durability of response, 12-month PFS, patient-reported quality of life, and safety are secondary goals. Enrollment is open right now.

Clinical trial identification
NCT03635567.

90 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cervical

Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Ad...
0:13:40
Podcast - Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_he...
22 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYNOTE826 #FDAApproval #CervicalCancer #Cancer #Research FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Re...
0:13:40
Mansoor Raza Mirza, MD @uni_copenhagen @UCPH_health #KEYN...
85 Views
1 year Ago
Cancer News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Podcast - Ignace B. Vergote, MD, PhD @UZLeuven #CervicalC...
17 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Cancer #Research 723MO - TV + Carbo In 1L Or + Pembro In Previously Treated  r/mCC
0:19:01
Ignace B. Vergote, MD, PhD @UZLeuven #CervicalCancer #Can...
55 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Podcast - Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 ...
50 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE826 #MetastaticCervicalCancer #Cancer #Research Presidential Symposium: KEYNOTE-826
0:06:40
Bradley Monk, MD @ArizonaOncology @GOG #ESMO21 #KEYNOTE82...
90 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 ...
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioState...
23 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James #ESMO21 #OvarianCancer #Cancer #Research Single-agent Anti-PD-1 Balstilimab Or In Combination With Anti-CTLA-4 Zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCC...
23 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast - David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
Podcast - David M. O'Malley, MD @omalleygynonc @OhioState...
217 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCCC_James @GOG @GOGPartners #ESMO21 #CervicalCancer #Cancer #Research - Balstilimab in combination with zalifrelimab
0:11:55
David M. O'Malley, MD @omalleygynonc @OhioStateMed @OSUCC...
78 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. #ASCO20 @MDAndersonNews - DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in comb...
0:03:40
Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. #ASCO20 @MDAn...
39 Views
2 years Ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Histopathologic validation of the sentinel node technique in early-stage cervical cancer patients - Will this affect clinicians - Dre Benedetta Guani  - University Hospital of Lausanne @O...
0:03:27
Histopathologic validation of the sentinel node technique...
15 Views
2 years Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592